TP53 and cancer: Both expression of p53 and p16 wasanalyzed simultaneously in the same lesions, but both the benign and themalignant lesions had immunoreactivity, making it impossible to identify thesame association found in HPV cases, where the immunoreactivity is associatedwith cancer (Thaiwong et al., 2018).Therefore, further studies are required to identify the mechanisms associatedwith this progression to cancer.